Presented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA
|
|
- Philomena Hicks
- 6 years ago
- Views:
Transcription
1 Is Associated With Improved Survival and Safety Compared to Colistin in Serious Carbapenemresistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study Lynn E. Connolly 1, Adrian M. Jubb 1, Bridget O Keeffe 1, Alisa W. Serio 1, Alex Smith 1, Jonathan Gall 1, Kevin M. Krause 1, James A. McKinnell 2, Epaminondas Zakynthinos 3, Valerie Riddle 4, and George L. Daikos 5 1 Achaogen, South San Francisco, CA, USA; 2 LA BioMed at Harbor-UCLA Medical Center, Los Angeles, CA, USA; 3 University Hospital, Larissa, Greece; 4 BioPharmAdvisors LLC, Parrish, FL, USA; 5 University of Athens, Athens, Greece Presented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA 1
2 Disclosures This presentation concerns a drug that is under clinical investigation and which has not yet been approved by any regulatory authority, including the US Food and Drug Administration (FDA) This drug is currently limited by law to investigational use, and no representation is made as to the safety or effectiveness for the purposes for which it is being investigated This presentation contains certain forward-looking statements reflecting Achaogen s current beliefs and expectations made pursuant to the safe harbor provisions of United States law, including, but not limited to, Achaogen s expectations relating to potential regulatory approval of plazomicin. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Achaogen s actual results, performance or achievements to be materially different from those implied by the forward-looking statements L.E. Connolly, A.M. Jubb, B. O Keeffe, A.W. Serio, A. Smith, J. Gall, and K.M. Krause are employees of and stockholders in Achaogen V. Riddle is President/Owner of BioPharmAdvisors LLC, a paid contractor to Achaogen J.A. McKinnell, E. Zakynthinos, and G.L. Daikos have received honoraria and served on advisory boards for Achaogen 2
3 Is a Next-generation Aminoglycoside for the Potential Treatment of MDR Enterobacteriaceae Structure protects it from most AMEs that inactivate other aminoglycosides 1 AMEs co-travel with other resistance mechanisms, including β-lactamases and carbapenemases 1 Inhibits bacterial protein synthesis and is rapidly bactericidal 2 Potent in vitro activity against: ESBL-producing Enterobacteriaceae 3 Carbapenem-resistant Enterobacteriaceae 3,4 Aminoglycoside-resistant Enterobacteriaceae 5 IV, once-daily 30-minute infusion AMEs ) AMEs Structure of plazomicin AMEs AMEs AMEs AME, aminoglycoside-modifying enzyme; ESBL, extended-spectrum b-lactamase; IV, intravenous; MDR, multidrug resistant. 1. Ramirez MS, Tolmasky ME. Drug Resist Updat. 2010;13: Thwaites M, et al. ASM Microbe Poster Galani I, et al. J Chemother. 2012;24: Livermore DM, et al. J Antimicrob Chemother. 2011;66: Almaghrabi R, et al. Antimicrob Agents Chemother. 2014;58:
4 Combating Antibiotic-resistant Enterobacteriaceae (CARE) A Phase 3 Study Evaluating the Efficacy and Safety of in the Treatment of Patients With Serious Infections due to Carbapenem-resistant Enterobacteriaceae (CRE) Primary Objective Evaluate the efficacy of plazomicin compared with colistin a in the treatment of BSI or HABP/VABP due to CRE based on primary endpoint: Day 28 all-cause mortality or significant disease-related complications (SDRC) b a or colistin in combination with adjunctive therapy of meropenem or tigecycline. b Within 7 days: New/worsening ARDS, new lung abscess or empyema, new-onset septic shock; persistence of bacteremia 5 days (BSI only); new-onset bacteremia (HABP/VABP only). This trial is registered at ClinicalTrials.gov: NCT ARDS, acute respiratory distress syndrome; BSI, bloodstream infection; HABP, hospital-acquired bacterial pneumonia; VABP, ventilator-associated bacterial pneumonia. 4
5 CARE Study Design Screening Treatment Follow-up Cohort 1: BSI, HABP/VABP Randomization 1:1 15 mg/kg q24h as 30-minute infusion (with TDM) Documented or presumed CRE infection Plus meropenem or tigecycline TOC EOS LFU Cohort 2: BSI, HABP/VABP, cuti/ap Colistin 300-mg loading dose; 5 mg/kg/d divided q8h or q12h as 60-minute infusion Documented or presumed CRE infection (with broader eligibility criteria) 15 mg/kg q24h as 30-minute infusion (with TDM) Adjunctive therapy per investigator s choice a TOC EOS LFU Up to 96 hours 7-14 days IV study drug therapy a Adjunctive therapy per investigator for BSI, HABP/VABP patients only; optional oral step-down after 4 days IV for cuti/ap. AP, acute pyelonephritis; cuti, complicated urinary tract infection; EOS, end of study; LFU, late follow-up; q8h, every 8 hours; q12h, every 12 hours; q24h, every 24 hours; TDM, therapeutic drug management; TOC, test of cure. 7 days from last dose IV study drug Day 28 Day 60 5
6 CARE Patient Disposition (Randomized Cohort 1) N = 39 ITT n = 18 All randomized patients n = 21 Colistin n = 18 MITT/Safety Patients who received any amount of study drug n = 21 MITT/Safety n = 17 mmitt Patients with CRE isolated from studyqualifying baseline specimen who received 1 dose of study drug n = 20 mmitt Primary efficacy analysis population included patients with BSI or HABP/VABP due to CRE. CRE defined as meropenem MIC of 4 µg/ml, or a meropenem MIC of 2 µg/ml and disk diffusion zone 19 mm on central laboratory testing. ITT, intent to treat; MIC, minimum inhibitory concentration; MITT, modified intent to treat; mmitt, microbiological modified intent to treat. 6
7 CARE Baseline Characteristics (Randomized Cohort 1) Well Balanced Across Treatment Groups Overall Baseline Characteristic (mmitt Population) (N = 17) Colistin (N = 20) Age, years, mean ± SD 66.7 ± ± 19 Male, n (%) 12 (70.6) 10 (50.0) APACHE II score, n (%) Infection type, n (%) Baseline pathogens, n (%) Creatinine clearance, n (%) a Initial adjunctive therapy, n (%) 15 to to 30 >30 BSI HABP/VABP Monomicrobial Polymicrobial >90 ml/min 90 ml/min CRRT Meropenem Tigecycline 10 (58.8) 6 (35.3) 1 (5.9) 14 (82.4) 3 (17.6) 14 (82.4) 3 (17.6) 4 (23.5) 7 (41.2) 4 (23.5) 6 (35.3) 11 (64.7) a Cockcroft-Gault estimation; baseline central laboratory data not available for subset of patients in each arm. 11 (55.0) 9 (45.0) 0 (0.0) 15 (75.0) 5 (25.0) 17 (85.0) 3 (15.0) 10 (50.0) 6 (30.0) 2 (10.0) 9 (45.0) 11 (55.0) APACHE II, Acute Physiology and Chronic Health Evaluation II; CRRT, continuous renal replacement therapy; SD, standard deviation. 7
8 CARE Efficacy Results (Randomized Cohort 1) Reduced Mortality at Day 28 for Versus Colistin BSI and HABP/VABP (mmitt Population) Difference (colistin minus plazomicin) (90% CI) Patients (%) (-0.7 to 51.2) 28.2 (0.7 to 52.5) 23.5% 50.0% 11.8% 40.0% Colistin /17 10/20 2/17 8/20 All-cause mortality at Day 28 or significant complications All-cause mortality at Day 28 Two-sided 90% confidence interval (CI) calculated based on the unconditional exact method. 8
9 CARE Efficacy Results (Randomized Cohort 1) Reduced Mortality at Day 28 and SDRCs for Versus Colistin in Key Subgroups of Interest Subgroup of Interest (mmitt Population) (N = 17) n/n1 (%) ACM at Day 28 or SDRCs Colistin (N = 20) n/n1 (%) APACHE II score /10 (20.0) 5/11 (45.5) APACHE II score /7 (28.6) 5/9 (55.6) Adjunctive meropenem a 1/6 (16.7) 5/10 (50.0) Adjunctive tigecycline a 3/12 (25.0) 6/11 (54.5) a 1 patient in each treatment group switched adjunctive therapy and was counted as having received both meropenem and tigecycline. Percentages are calculated as n (number of patients in specified category)/n1 (number of patients in the specified subgroup). ACM, all-cause mortality; SDRC, significant disease-related complications. 9
10 CARE Efficacy Results (Randomized Cohort 1) Reduced Mortality at Day 28 for Versus Colistin in BSI BSI Subgroup (mmitt Population) Difference (colistin minus plazomicin) (90% CI) (9.4 to 65.5) 32.9 (4.0 to 60.1) 53.3% Patients (%) % 40.0% Colistin 10 0 All-cause mortality at Day 28 or significant complications 7.1% 2/14 8/15 1/14 6/15 All-cause mortality at Day 28 Two-sided 90% CI calculated based on the unconditional exact method. 10
11 CARE Efficacy Results (Randomized Cohort 1) Sustained Survival Benefit in -treated Patients With BSI day Survival in BSI Subgroup (mmitt Population) HR for death (plazomicin:colistin) (90% CI) 0.37 (0.15 to 0.91) Patients alive (%) Colistin Censored Days Estimate of hazard ratio (HR) calculated as plazomicin:colistin based on Cox proportional hazards regression model. 11
12 CARE Efficacy Results (Randomized Cohort 1) Favorable Microbiological Response Higher in BSI Patients Treated With Versus Colistin BSI Subgroup (mmitt Population) Favorable response (%) % 92.9% 60.0% 53.3% 13/14 9/15 13/14 8/15 EOT TOC Colistin A favorable microbiological response for BSI requires confirmed negative results in 2 consecutive blood cultures measured on separate study days, with no recurrence on or prior to the specified visit. EOT, end of treatment (Day 7-14); TOC, test of cure (7 days ±2 days after EOT). 12
13 CARE Patient Disposition (Observational Cohort 2) N = 30 ITT n = 30 Safety n = 27 mmitt n = 14 BSI n = 9 HABP/VABP n = 4 cuti Cohort 2 included patients with BSI or HABP/VABP due to CRE who were ineligible for Cohort 1, as well as patients with cuti due to CRE. ITT, intent to treat; mmitt, microbiological modified intent to treat. 13
14 CARE Baseline Characteristics (Observational Cohort 2) Cohort 2 Is Distinct From Cohort 1 Baseline Characteristic (mmitt Population) (N = 17) n (%) Cohort 1 Cohort 2 Colistin (N = 20) n (%) (N = 27) n (%) Age, mean ± SD 66.7 ± ± ± 17 Male 12 (70.6) 10 (50.0) 21 (77.8) APACHE II score a <15 15 to to 30 >30 Infection type Baseline pathogens Creatinine clearance b BSI HABP/VABP cuti Monomicrobial Polymicrobial >90 ml/min 90 ml/min CRRT 0 (0.0) 10 (58.8) 6 (35.3) 1 (5.9) 14 (82.4) 3 (17.6) 0 14 (82.4) 3 (17.6) 4 (23.5) 7 (41.2) 4 (23.5) 0 (0.0) 11 (55.0) 9 (45.0) 0 (0.0) 15 (75.0) 5 (25.0) 0 17 (85.0) 3 (15.0) 10 (50.0) 6 (30.0) 2 (10.0) 11/23 (47.8) 7/23 (30.4) 5/23 (21.7) 0 (0.0) 14 (51.9) 9 (33.3) 4 (14.8) 14 (51.9) 13 (48.1) 8 (29.6) 14 (51.9) 3 (11.1) Initial adjunctive therapy a Meropenem Tigecycline Other 6 (35.3) 11 (64.7) 0 (0.0) a 4 cuti patients in Cohort 2 did not receive adjunctive therapy or have APACHE II score collected. b Cockcroft-Gault estimation; baseline central laboratory data not available for subset of patients in each arm. 9 (45.0) 11 (55.0) 0 (0.0) 4/23 (17.4) 17/23 (73.9) 2/23 (8.7) APACHE II, Acute Physiology and Chronic Health Evaluation II; CRRT, continuous renal replacement therapy; SD, standard deviation. 14
15 CARE Efficacy Results (Observational Cohort 2) Low Mortality in BSI Subgroup Supportive of Findings in Cohort 1 BSI Subgroup (mmitt Population) Patients (%) % 30.0% 14.3% 10.0% 5/14 3/10 2/14 1/10 All-cause mortality at Day 28 or significant complications Overall (All CRE) CRE without Acinetobacter or Pseudomonas co-infection All-cause mortality at Day 28 All patients meeting primary endpoint due to SDRC alone had persistent CRE bacteremia on or after Day 5 Additional gram-negative pathogens include Acinetobacter spp. and Pseudomonas aeruginosa, which were an exclusion criterion for Cohort 1. SDRC, significant disease-related complications. 15
16 CARE Overall Summary of AEs and SAEs Favorable Safety Profile for Versus Colistin Adverse Event (Safety Population) (N = 18) n (%) Cohort 1 Cohort 2 Colistin (N = 21) n (%) (N = 30) n (%) AE 16 (88.9) 21 (100.0) 26 (86.7) Study drug-related 5 (27.8) 9 (42.9) 5 (16.7) Led to discontinuation of study drug 2 (11.1) 1 (4.8) 3 (10.0) Related to renal function 6 (33.3) 11 (52.4) 9 (30.0) SAE 9 (50.0) 17 (81.0) 20 (66.7) Study drug-related 1 (5.6) 4 (19.0) 0 (0.0) Led to death (up to Day 60 visit) 8 (44.4) 13 (61.9) 12 (40.0) Related to renal function 2 (11.1) 6 (28.6) 1 (3.3) No study drug-related deaths and no events of ototoxicity were reported AE, adverse event; SAE, serious adverse event. 16
17 CARE Laboratory Parameters Associated With Renal Function Lower Incidence and Magnitude of Serum Creatinine Increases for Versus Colistin Number of patients Cohort 1 (Safety Population) (n(n=12) = 2/12) Colistin (n (N=16) = 8/16) Majority (6/9) of serum creatinine increases in Cohort 2 patients were <1.0 mg/dl Serum creatinine increase 0.5 to <1.0 mg/dl 1.0 to <1.5 mg/dl 1.5 to <2.0 mg/dl 2.0 to <3.0 mg/dl Baseline serum creatinine defined as the last central laboratory measurement prior to the first dose of study drug. Patients starting CRRT prior to baseline were excluded from the analysis, as were all postbaseline serum creatinine measurements collected after start of CRRT. 17
18 CARE Conclusions Patients with serious CRE infections had high mortality and disease-related complications When used as part of a combination regimen, plazomicin treatment was associated with reduced all-cause mortality at Day 28 overall, and in the subgroup of BSI patients, compared with colistinbased treatment The survival benefit in plazomicin-treated BSI patients was sustained through Day 60 The higher microbiological response rate in plazomicin-treated BSI patients supports the mortality benefit observed The low mortality rate in Cohort 2 BSI patients is supportive of findings in Cohort 1 was associated with a favorable safety profile compared with colistin, including lower incidence and magnitude of serum creatinine elevations when used as part of a combination regimen for the treatment of life-threatening infections due to CRE Data from the CARE study suggest that plazomicin could offer an important new potential treatment option for patients with serious infections due to CRE 18
19 Acknowledgments The authors thank the investigators, patients, and families involved in this clinical trial program This project has been funded in whole or in part with Federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO C Medical writing support was provided by Jean Turner of PAREXEL and funded by Achaogen 19
27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, April 22-25, 2017
Is Associated With Improved Survival and Safety Compared With in the Treatment of Serious Infections Due to Carbapenem-resistant Enterobacteriaceae: Results of the CARE Study Lynn E. Connolly 1, Adrian
More informationPlazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study
Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study Daniel J. Cloutier 1, Loren G. Miller 2, Allison S. Komirenko 1,
More informationAchaogen Launches ZEMDRI (plazomicin), a Once-Daily Aminoglycoside for use in complicated Urinary Tract Infections (cuti)
Achaogen Launches ZEMDRI (plazomicin), a Once-Daily Aminoglycoside for use in complicated Urinary Tract Infections (cuti) -- ZEMDRI now available for ordering in the U.S. -- -- ZEMDRI demonstrated in vitro
More informationPlazomicin for complicated urinary tract infection
October 2016 Horizon Scanning Research & Intelligence Centre Plazomicin for complicated urinary tract infection NIHR HSRIC ID: 9787 Lay summary Serious infections caused by Gram-negative bacteria are becoming
More informationNDA Briefing Document Anti-Infective Drugs Advisory Committee 05 December 2014
CEFTAZIDIME-AVIBACTAM FOR INJECTION for Treatment of Complicated Intra-abdominal Infection (used in combination with metronidazole), Complicated Urinary Tract Infection including Acute Pyelonephritis,
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationLa batteriocidia sierica: passato e presente
Genova, 23 settembre 2016 La batteriocidia sierica: passato e presente Dott.ssa Maddalena Giannella Clinica di Malattie Infettive AOU Policlinico Sant Orsola Malpighi Case 1 Case 2 Summary: Cured of cancer
More informationAntibiotic Treatment of GNR MDR Infections. Stan Deresinski
Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility
More informationNightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017
Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS
More informationInterim Results of Expanded Access Program of AB-SA01 and AB-PA01 for Treatment of Serious and Life-threatening S. aureus and P. aeruginosa Infections
Advancing bacteriophage therapeutics for patients with antibioticresistant infections Interim Results of Expanded Access Program of AB-SA01 and AB-PA01 for Treatment of Serious and Life-threatening S.
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationArticles. Funding AstraZeneca.
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial Antoni Torres, Nanshan Zhong,
More informationwithout the permission of the author Not to be copied and distributed to others
Emperor s Castle interior-prato What is the Role of Inhaled Polymyxins for Treatment of Respiratory Tract Infections? Helen Giamarellou CONCLUSIONS: Patients with Pseudomonas and Acinetobacter VAP may
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationBelow is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017:
SHIONOGI TO HIGHLIGHT RESEARCH ON CEFIDEROCOL (S-649266), A SIDEROPHORE CEPHALOSPORIN, AND S-033188, A CAP-DEPENDENT ENDONUCLEASE INHIBITOR FOR TREATMENT OF INFLUENZA, AT IDWEEK 2017 OSAKA, Japan and FLORHAM
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationIs the package insert correct? PK considerations
Is the package insert correct? PK considerations Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationAminoglycosides John A. Bosso, Pharm.D.
AMINOGLYCOSIDES Therapeutics/PHRMP-73 Aminoglycoside Mechanism of Action Aminoglycosides bind to 30s ribosomal subunit resulting in mistranslation of mrna thus disrupting protein synthesis. They are rapidly
More informationCURRENT GUIDELINES FOR SEPSIS MANAGEMENT
HELLENIC SEPSIS STUDY GROUP www.sepsis.gr CURRENT GUIDELINES FOR SEPSIS MANAGEMENT Evangelos J. Giamarellos-Bourboulis, MD, PhD Associate Professor of Medicine 4 th Department of Internal Medicine, National
More informationTRANSPARENCY COMMITTEE. Opinion. 07 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 07 January 2009 500 mg, powder for solution for perfusion B/10 bottles (CIP: 387 355-6) Applicant: JANSSEN-CILAG doripenem
More informationHealthy Adult cuti Patient. Cmax (mcg/ml)(mean ± SD) 73.7 ± ± 113. Vd (L)(mean ± SD) 17.9 ± ± 12.1
Brand Name: Zemdri Generic Name: plazomicin Manufacturer: Achaogen, Inc Drug Class: aminoglycoside antibacterial Uses: 1-5 Labeled: treatment of complicated urinary tract infections (cuti), including pyelonephritis,
More informationDiane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center
Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center The information disseminated in this lecture is given in my personal
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationUse of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles
with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition
More informationTherapy of MDR/XDR Gram-negative bacteria: dealing with the devil. CRE: high dosing, how much? by author
Therapy of MDR/XDR Gram-negative bacteria: dealing with the devil CRE: high dosing, how much? George L. Daikos, MD National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece
More informationGuess or get it right?
Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationCellceutix Corporation Beverly, MA USA Abstract 2969; Presentation 0195; Hall J, 4:00pm. April 27, 2015
ECCMID 2015 Copenhagen, Denmark 25 28 April 2015 Cellceutix Corporation Beverly, MA USA www.cellceutix.com A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin
More informationTreatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
REVIEW ARTICLE Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections Haley J. Morrill, 1,2 Jason M. Pogue, 3 Keith S. Kaye, 4 and Kerry L. LaPlante 1,2,5 1 Veterans Affairs Medical Center,
More informationAntibiotics to treat multi-drug-resistant bacterial infections
Antibiotics to treat multi-drug-resistant bacterial infections July 2013 JUNE 2013 Copyright 2013 Tetraphase Pharmaceuticals, Inc. 1 Forward Looking Statements and Other Important Cautions Any statements
More informationClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationAntibiotic Usage Related to Microorganisms Pattern and MIC
Antibiotic Usage Related to Microorganisms Pattern and MIC DR. Dr. Latre Buntaran Sp.MK(K) Secretary General PERDALIN Head of Compartment of Infection Control PERSI Doripenem: Potent
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationXERAVATM (eravacycline): A Novel Fluorocycline Antibacterial
XERAVATM (eravacycline): A Novel Fluorocycline Antibacterial Matteo Bassetti, MD, PhD Infectious Diseases Division University of Udine and Santa Maria Misericordia University Hospital Udine, Italy Disclosures
More informationNew insights in antibiotic and antifungal therapy in the compromised host
New insights in antibiotic and antifungal therapy in the compromised host Claudio Viscoli University of Genova Ospedale Policlinico San Martino, Genova Potential conflicts of interest (last 5 years) Received
More informationTP Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals
TP-676 Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals Tetraphase Pharmaceuticals Overview Tetraphase is developing novel antibiotics for serious and life-threatening Gram-negative MDR
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationHOSPITAL EPIDEMOLOGY AND INFECTION CONTROL: STANDARD AND TRANSMISSION-BASED ISOLATION
Appendix 1: Carbapenem-Resistant Enterobacteriacaea (CRE) I. Definition: 2015 CDC definition of CRE are Enterobacteriaceae 1 that are: A. Resistant to any carbapenem antimicrobial (i.e., minimum inhibitory
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationContinuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients
Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients Jan O Friedrich, MD DPhil Associate Professor of Medicine, University of Toronto Medical Director, MSICU St. Michael s Hospital,
More informationThe Antibiotic Resistance Laboratory Network
The Antibiotic Resistance Laboratory Network 1 Antibiotic Resistance in the United States Sickens >2 million people per year Kills at least 23,000 people each year Plus 15,000 each year from C. difficile
More informationNew Antimicrobials: Now and In the Future
New Antimicrobials: Now and In the Future David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical School Conflicts of Interest Melinta
More informationReporting blood culture results to clinicians: MIC, resistance mechanisms, both?
Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska
More informationPHARMACOKINETICS OF COLISTIN IN
PHARMACOKINETICS OF COLISTIN IN CRITICALLY ILL PATIENTS WITH MULTIDRUG-RESISTANT GRAM- NEGATIVE BACILLI INFECTION JOURNAL CLUB PRESENTATION Amal M. Al-Anizi, PharmD Candidate KSU, Infectious disease rotation
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationComparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects
Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects Karolyn S. Horn, Mark H. Gotfried, Judith N. Steenbergen,
More information2/6/14. What s Hot in ID Objectives
What s Hot in ID 2014 James S. Lewis II, Pharm.D., FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Portland, OR Objectives Describe highlights of the Interscience Conference
More informationZEMDRI Prescribing Information 1. Recommended initial dosage regimen for patients with renal impairment is shown in the table below. (2.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZEMDRI safely and effectively. See full prescribing information for ZEMDRI. ZEMDRI (plazomicin) injection,
More informationDevelopment of Drugs for Bacteremia
Development of Drugs for Bacteremia Charles Knirsch, MD, MPH VP, Clinical Research Pfizer Inc 1 Bacteremia Guidance Issues EMA guidance suggests that bacteremia is not a primary diagnosis but represents
More informationESCMID Online Lecture Library. by author
Novel PK/PD data on the optimisation of colistin and the carbapenems Diamantis Plachouras Athens, Greece Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course, 31
More informationEnpr-EMA PAEDIATRIC ANTIBIOTIC WORKING GROUP
Enpr-EMA PAEDIATRIC ANTIBIOTIC WORKING GROUP Rationale and outlook Laura Folgori Clinical Research Fellow Paediatric Infectious Diseases Research Group St George s University of London RATIONALE The work
More informationChallenges of HABP/VABP Trials
Challenges of HABP/VABP Trials CTTI - 22 April, 2013 H. David Friedland, MD Cerexa Inc., a wholly owned subsidiary of Forest Laboratories Disclosures Employee of Cerexa, a wholly owned subsidiary of Forest
More informationRAPID COMMUNICATION. Maura S. de Oliveira, I Silvia Figueiredo Costa, II Ewerton de Pedri, II Inneke van der Heijden, II Anna Sara S.
RAPID COMMUNICATION The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam
More informationSepsis Treatment: Early Identification Remains the Key Issue
Sepsis Treatment: Early Identification Remains the Key Issue Marin H. Kollef, MD Professor of Medicine Washington University School of Medicine Director, Medical Critical Care Director, Respiratory Care
More informationFrequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI
More informationTreatment Strategies for Infections due to MDR-GNR
Treatment Strategies for Infections due to MDR-GNR Michael Satlin, MD Instructor in Medicine Division of Infectious Diseases Weill Cornell Medical College, New York, NY October 16, 2012 1 2 Faculty Disclosure
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationSuperhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia
Superhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia Brandon Dionne, PharmD, BCPS, AAHIVP Assistant Clinical Professor Northeastern University Seth Housman, PharmD, MPA Clinical Assistant
More informationUrinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
More informationGuidelines. 14 Nov Marc Bonten
Guidelines 14 Nov 2014 Marc Bonten Treatment of Community-Acquired Pneumonia SWAB/ NVALT guideline 2011, replaced SWAB guideline 2005 Empirical treatment must cover the most likely causative pathogen.
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationNew treatments of multidrug-resistant Gram-negative ventilatorassociated
Review Article Page 1 of 22 New treatments of multidrug-resistant Gram-negative ventilatorassociated pneumonia Garyphallia Poulakou 1, Styliani Lagou 1, Drosos E. Karageorgopoulos 2, George Dimopoulos
More informationOptimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches
Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator
More informationAMINOGLYCOSIDES TDM D O N E B Y
AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationSupplementary Online Content 2. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on
Supplementary Online Content 2 Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated
More informationCHMP extension of indication variation assessment report
23 April 2015 EMA/CHMP/245949/2015 adopted Committee for Medicinal Products for Human Use (CHMP) Invented name: Tygacil International non-proprietary name: TIGECYCLINE Procedure No. EMEA/H/C/000644/II/0092
More informationNew Medicines Committee Briefing. July Fosfomycin trometamol for the treatment of multidrug resistant urinary tract infection
New Medicines Committee Briefing July 2014 Fosfomycin trometamol for the treatment of multidrug resistant urinary tract infection (unlicensed indication) Fosfomycin trometamol to be reviewed for use within:
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationCurrent concepts in combination antibiotic therapy for critically ill patients
Short Communication Current concepts in combination antibiotic therapy for critically ill patients Armin Ahmed, Afzal Azim, Mohan Gurjar, Arvind Kumar Baronia Abstract Widespread emergence of multidrug
More informationTerapia delle infezioni da Pseudomonas aeruginosa MDR
Verona 23 ottobre 2010 Terapia delle infezioni da Pseudomonas aeruginosa MDR Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Global resistance surveillance of Pseudomonas aeruginosa
More informationAugmented Renal Clearance: Let s Get the Discussion Flowing
Augmented Renal Clearance: Let s Get the Discussion Flowing Terry Makhoul, PharmD PGY-2 Emergency Medicine Pharmacy Resident University of Rochester Medical Center Strong Memorial Hospital Disclosures
More informationESCMID Online Lecture Library. by author
Microbiological evaluation: how to report the results Alvaro Pascual MD, PhD Infectious Diseases and Clinical Microbiology Unit. University Hospital Virgen Macarena University of Sevilla BSI management
More informationLa neutropenia febbrile
XII Corso Avanzato di Terapia Antibiotica Pisa, 15-16 novembre 2017 La neutropenia febbrile Alessandra Micozzi Dipartimento di Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma Fever developing
More informationThe clinical implication and prognostic predictors of Tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii
Journal of Infection (2011) 63, 351e361 The clinical implication and prognostic predictors of Tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii R 陳南丞 VS 余文良醫師 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時,
More informationEducational Workshop
Educational Workshop EW02: Management of severe sepsis and septic shock anno 2015 Arranged with ESGBIS & International Sepsis Forum (ISF) Convenors: W. Joost Wiersinga, Amsterdam, NL Tom van der Poll,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal catastrophes in ICU, 1017 1044. See also specific types, e.g., Abdominal compartment syndrome treatment of, 1032 1037 antimicrobial,
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationChan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels
Online supplement to: Chan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels Supplementary Figure 1. CONSORT disposition
More informationAVYCAZ (ceftazidime and avibactam) Dosing and Administration
AVYCAZ (ceftazidime and avibactam) Dosing and Administration DOSAGE OF AVYCAZ BY INDICATION IN PATIENTS WITH NORMAL RENAL FUNCTION (CREATININE CLEARANCE GREATER THAN 50 ml/min) 1 DOSAGE ADJUSTMENTS IN
More informationMechanisms of Resistance to Ceftazidime-Avibactam. Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics.
Mechanisms of Resistance to Ceftazidime-Avibactam Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics UCLA, January 2015 62 year old woman with advanced pancreatic cancer Vomiting
More informationAAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00931-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationNational Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats
National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats Jean B. Patel, PhD, D(ABMM) Science Lead, Antibiotic Resistance and Coordination Unit Centers for
More informationReports of efficacy and safety studies of primary immunodeficiency
2. SYNOPSIS TITLE OF STUDY: Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of IGIV3I GRIFOLS [Immune Globulin Intravenous (Human)] for Replacement Therapy in Primary Immunodeficiency
More informationDetermining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00838-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 1 2 Determining the
More informationD DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2
Journal of Pharmacy and Pharmacology 5 (2017) 607-615 doi: 10.17265/2328-2150/2017.09.001 D DAVID PUBLISHING Comparative Evaluation of Pharmacist-Managed Vancomycin Dosing in a Community Hospital Following
More informationR EVIEWS OF T HERAPEUTICS
R EVIEWS OF T HERAPEUTICS Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae Sarah Christina Jane Jorgensen, 1 and Michael Joseph Rybak 1,2,3, * 1 Anti-infective
More informationTreatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae medicine.missouri.edu/jahm/treatment-options-urinary-tract-infections-caused-extended-spectrum-β-lactamase-producingescherichia-coli-klebsiella-pneumoniae/
More informationNONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN
NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial
More informationSensitivity of Surveillance Testing for Multidrug-Resistant Gram-Negative Bacteria in the
JCM Accepts, published online ahead of print on 20 August 2014 J. Clin. Microbiol. doi:10.1128/jcm.02369-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Sensitivity of Surveillance
More informationResurgence of older oral therapies in OPAT: options for OPAT sparing
Resurgence of older oral therapies in OPAT: options for OPAT sparing Dr Carolyn Hemsley Consultant in Infectious Disease and Microbiology, Guy s and St Thomas, London Why do we intravenous therapy? Evidence
More informationCystatin C: A New Approach to Improve Medication Dosing
Cystatin C: A New Approach to Improve Medication Dosing Erin Frazee Barreto, PharmD, MSc, FCCM Assistant Professor of Pharmacy and Medicine Kern Scholar, Center for the Science of Health Care Delivery
More information